and a lactose-free diet (26%). There were similar clinical responses among the three diets (Figure 1 ). Twenty-five to thirty percent reported no change in joint symptoms whereas 20-30% reported improved pain or joint swelling. Sixty-one (34%) parents were willing to participate in a 3-month dietary intervention study and 78 (44%) parents answered "it depends". Background: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory disorder characterized by fibrotic lesions infiltrated by IgG4 positive plasma cells (1). The prompt clinical responses obtained after B cell depletion with rituximab in IgG4-RD patients suggest that B lymphocytes drive the pathogenesis of this condition and sustain disease activity (2). This conclusion, however, requires further confirmation because IgG4-RD responds also to non-B cell depleting therapies such as glucocorticoids and methotrexate Objectives: To evaluate the effects of glucocorticoids and methotrexate-based therapeutic regimens on B lymphocyte subpopulations in patients with IgG4-RD. Methods: Sixteen patients with active IgG4-RD were studied. FACS analysis was performed on peripheral blood in order to identify the following B cell subpopulations: total B cells (CD19+CD20-and CD19+CD20+ cells), circulating plasmablasts (CD19+CD20-CD27+CD38++ cells), naïve B cells (CD19+CD20+CD27-CD38+ cells), memory B cells (CD19+CD20-CD27+CD38-cells), circulating plasma cells (CD38+CD138+ cells). Disease activity was assessed by means of the IgG4-RD responder index (IgG4-RD RI). Flow cytometry was performed at baseline and after six months of immunosuppressive therapy with glucocorticoids (0.6-1mg/kg/day) and/or methotrexate (10-20mg/week). 16 sex and age matched healthy subjects were used as controls. Results: At baseline, circulating plasmablasts were expanded in IgG4-RD patients (median 3780 cell/mL; range 330-9300) compared to controls (median 280 cell/mL; range 0-1000) (p<0.05); total B cells (median 133000 cell/mL; range 34000-569000) and naïve B cells (median 13080 cell/mL; range 1970-64270) were reduced in IgG4-RD patients compared to controls (median 280 cell/mL; range 194-330; and median 54020 cell/mL; range 21050-106780, respectively) (p<0.05). No circulating plasma cells were detected in healthy controls. No differences in memory B cells were observed (p>0.05). Circulating plasmablasts but not other B cell subsets positively correlated with serum IgG4 levels, number of organ involved, and IgG4-RD RI (p<0.05). At six months follow-up, the median IgG4-RD RI decreased from 9 to 2. Circulating plasmablasts, circulating plasma cells, and naïve B cells counts decreased in all patients together with disease improvement (p=0.0002, 0.0002 and 0.025 compared to baseline values, respectively); total B cells and memory B cells were unaffected by immunosuppressive therapy. Objectives: To characterize the main features at presentation of sarcoidosis in a large multicenter cohort from Southern Europe.
Conclusions

Methods:
In January 2016, the Autoimmune Diseases Study Group (GEAS-SEMI) created a national registry (SARCOGEAS) of patients with sarcoidosis. Sarcoidosis was diagnosed in agreement with the criteria proposed by the ATS/ERS/WASOG 1999 statement, and extrathoracic disease was classified with the 2014 WASOG instrument. Results: The cohort consisted of 1082 patients (82% biopsy-proven), including 618 (57%) women and 464 (43%) men, with a mean age at diagnosis of 47yrs; 140 (13%) patients were born outside Spain, 965 (89%) were White, 69 (6%) Hispanic, 30 (3%) Black/African American and 18 (2%) Asian. Thoracic involvement was present at diagnosis in 979 (90%) patients, including 437 (40%) patients with stage I, 374 (35%) with stage II, 123 (11%) with stage III and 26 (2%) with stage IV. The most frequently reported extrathoracic involvements at diagnosis were cutaneous in 385 (36%) patients, extrathoracic lymph nodes in 218 (20%), liver involvement in 151 (14%) and ocular involvement in 118 (11%). Potentially life-threatening WASOG involvements were reported in frequencies less than 10%, including neurological involvement in 77 (7%) patients, kidney involvement in 59 (5%) or cardiac involvement in 21 (2%). Therapeutic approaches at diagnosis included the use of oral glucocorticosteroids in 637 (59%) patients, immunosuppressive agents in 84 (8%, mainly methotrexate in 63 patients) and biological agents in 15 (1%, mainly infliximab in 10 cases).
Conclusions:
In this large series of sarcoidosis from Southern Europe, clinical presentation is dominated by adenopathies (both thoracic and extrathoracic) and cutaneous involvement (erythema nodosum), with lower frequencies in the main extrathoracic involvements than that reported in US and Japanese series. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4387
